0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 03:47 ET (08:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.